Clinical Trials Browser

INDUSTRY × Head and Neck Neoplasms × Gefitinib × Clear all

NCT00684385 2019-03-14

An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck

Approved for marketing

Head & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms

NCT00233636 2011-01-27

Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck

Phase 2 Withdrawn

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT00242762 2011-01-27

ZD1839 (IRESSA™) in Combination With Docetaxel & Cisplatin in Subjects With Metastatic Head & Neck Cancer

Phase 2 Completed

Head and Neck Neoplasms

NCT00242749 2009-04-23

IRESSA in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma

Phase 2 Completed

Head and Neck Neoplasms

NCT00255476 2009-04-23

The IRESSA Novel Head and Neck Chemotherapy Evaluation Study

Phase 2 Completed

Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT00228488 2007-12-19

Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma

Phase 2 Completed

Head and Neck Neoplasms

NCT00239304 2007-12-18

Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally Advanced Head & Neck Cancer

Phase 1/2 Completed

Head and Neck Neoplasms